Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•03/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 product revenue $125.5 million, up 19% year-over-year
- ➤IBSRELA revenue $96.3 million, up 23% year-over-year
- ➤XPHOZAH revenue $29.2 million, up 7% year-over-year
- ➤2026 IBSRELA revenue guidance reiterated at $350-$370 million
- ➤ACCEL Phase 3 CIC enrollment completed ahead of schedule
Expert Statements
Mike Raab, President and Chief Executive Officer of Ardelyx
“Our third quarter results reflect the strength of the foundation we’ve built”
Mike Raab, President and Chief Executive Officer of Ardelyx
“IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter.”
Mike Raab, President and Chief Executive Officer of Ardelyx
“With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen.”
Mike Raab, President and Chief Executive Officer of Ardelyx
“Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”
Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year
IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million
Get started
Create a free account to read the full story.